Calcitonin gene-related peptide is potential therapeutic target of osteoporosis
Wu H., Lin XQ., Long Y., Wang J.
Narrative Review, published in Heliyon (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Heliyon (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 36536904
- PMCID
- PMC9758432
- DOI
- 10.1016/j.heliyon.2022.e12288
- Citations
- 13
Abstract (original English)
Osteoporosis is a skeletal disorder characterised by the decrease of bone mineral density and is becoming prevalent with the entry of an ageing era. There are two catalogues of osteoporosis, including primary osteoporosis and secondary osteoporosis, according to the pathological causes. Since the demonstrations of osteoporosis are usually covered by other diseases, its therapeutic strategies are not satisfactory for both patients and clinicians. Calcitonin gene-related peptide (CGRP) is a peptide expressed in both bone tissues and peripheral nerves innervating bone tissue, and its expression in osteoporosis patients is increased. Recent studies have indicated that CGRP could promote the osteogenesis by osteblasts and bone absorption by osteoclasts, thus maintaining the bone homeostasis. The effects of CGRP on bone homeostasis are related with its promotion of angiogenesis through vascular endothelial growth factor and its modulation of multiple signal pathways including receptor activator of nuclear factor kappa-Β ligand. In addition, CGRP could interact with neuronal system through neural growth factor to modulate osteoporosis. Application of implants or nanoparticles also verified the beneficial effect of CGRP on osteoporosis. There studies imply a great therapeutic potential of CGRP in treating osteoporosis. Although massive studies about CGRP in osteoporosis have been perfo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.